|
Plenary Lectures
(PDF file can be downloaded here.)
| 9:30-10:30 |
|
Chairman:
Peter Andrews
|
|
PL-1 |
Viruses and
Killer T Cells
Peter C. Doherty (The University of Melbourne, AUSTRALIA) |
| 10:30-11:30 |
|
Chairman:
Masaaki Hirobe
|
|
PL-2 |
Discovery
and Development of Drugs on a Global Basis
Hatsuo Aoki (Fujisawa Pharmaceutical Co., Ltd., JAPAN) |
| 9:30-10:30 |
|
Chairman:
Teruhisa Noguchi
|
|
PL-3 |
The Chemistry
of Drug Discovery: Short and Long Term Strategies
Robert W. Armstrong (Eli Lilly and Company, Indianapolis IN, USA) |
| 10:30-11:30 |
|
Chairman:
Michio Ui
|
|
PL-4 |
Mechanism
of Intacellular Transport and Kinesin Superfamily Proteins (KIFs):
Genes, Structure, Dynamics, Functions, and Diseases
Nobutaka Hirokawa (The University of Tokyo, JAPAN) |
| 9:30-10:30 |
|
Chairman:
Hiroshi Terada
|
|
PL-5 |
Drug
Delivery - What Will Be the Future?
Hans E. Junginger (Leiden University, THE NETHERLANDS) |
| 10:30-11:30 |
|
Chairman:
Masakatsu Shibasaki
|
|
PL-6 |
Molecular
Machines for Protein Degradation
Robert Huber (Max-Planck-Institut für Biochemie, Martinsried,
GERMANY) |
Invited Lectures
|
|
Chairman:
Kazuhiko Tanzawa
|
| <New
Drug Target-1> |
| 14:00-14:30 |
L-1 |
Can Microbial
Genomics Enable the Discovery of Novel Antimicrobial Drugs?
Mark Wuonola (AstraZeneca, Waltham MA, USA) |
| 14:30-15:00 |
L-2 |
Rapid Identification
of Drug-targetable Genes by siRNA and Ribozyme Libraries
Kazunari Taira (The University of Tokyo, JAPAN) |
| 15:00-15:30 |
L-3 |
Discovery
of Ghrelin: Its Structure and Physiological Significance
Kenji Kangawa (National Cardiovascular Center Research Institute &
Kyoto University Hospital, JAPAN) |
| 15:30-16:00 |
|
<Coffee
Break> |
|
|
Chairman:
Akira Matsuda
|
| <New
Drug Target-2> |
| 16:00-16:30 |
L-4 |
New Therapeutic
Opportunities in Sulfation Pathways
Carolyn R. Bertozzi (University of California, Berkeley CA, USA) |
| 16:30-17:00 |
L-5 |
Discovering
Anti-SARS Drugs Based on Host Protein-Virus Protein Interaction
Hua-Liang Jiang (Chinese Academy of Sciences Shanghai, CHINA)
|
| 17:00-17:30 |
L-6 |
Structural
Biology, Multivalency and Pharmacokinetic Optimisation in Drug Design
Simon Tucker (Biota Holdings Limited, Melbourne, AUSTRALIA)
|
|
|
Chairman:
Takehiko Naka
|
| <Alzheimer
Disease> |
| 14:00-14:30 |
L-7 |
β-Amyloid
and Presenilins as Therapeutic Targets for Alzheimer's Disease
Takeshi Iwatsubo (The University of Tokyo, JAPAN) |
| 14:30-15:00 |
L-8 |
Trends in
Development Drugs for Alzheimer's Disease
Hachiro Sugimoto (Kyoto University, JAPAN) |
| <Enzyme
Inhibitor> |
| 15:00-15:30 |
L-9 |
Design,
Synthesis, and Biological Evaluation of Novel Pyrrolo[3,2-d]
pyrimidin-4-one Derivatives as Selective PDE5 Inhibitors
Dae-kee Kim (In2Gen Co., Ltd., KOREA) |
| 15:30-16:00 |
|
<Coffee
Break> |
|
|
Chairman:
Henk Timmerman
|
| <Anti-diabetes> |
| 16:00-16:30 |
L-10 |
Discovery
and Development of a New Insulin Sensitizer, Pioglitazone
Yu Momose (Takeda Chemical Industries, Ltd., JAPAN) |
| <Roles
of Genomics in Drug Discovery> |
| 16:30-17:00 |
L-11 |
The Implications
of Genomics and Genetics for Drug Discovery
Trevor Woodage (Applied Biosystems, Rockville MD, USA) |
| 17:00-17:30 |
L-12 |
Efficient
Discovery of Disease Susceptibility Genes with Newly Developed Gene-Centric
Even-Spacing Common Shared SNPs Markers - Toward the Genomic Drug
Discovery for Diabetes
Mitsuo Itakura (The University of Tokushima, JAPAN) |
|
|
Chairman:
Toshio Fujita
|
| <Predictive
Informatics> |
| 13:00-13:30 |
L-13 |
Drug-like
Properties: The Use of the 'Rule of 5' and Other Property Filters
in Medicinal Chemistry
Christopher A. Lipinski (Pfizer, Groton CT, USA) |
| 13:30-14:00 |
L-14 |
From HITS
to Drugs: Efficient Lead Optimization Using ADME-T Properties and
Computational Filters
Gregor Zlokarnik (Vertex Pharmaceuticals Incorporated, San Diego CA,
USA) |
| 14:00-14:30 |
L-15 |
Robust Methods
for ADMET Prediction and Drug Discovery
David A. Winkler (CSIRO Molecular Science, Clayton South, AUSTRALIA) |
|
|
Chairman:
Li-He Zhang
|
| <New
Drug Development> |
| 13:00-13:30 |
L-16 |
DJ-927, a
Novel Orally Active Taxane
Tsunehiko Soga (Daiichi Pharmaceutical Co., Ltd., JAPAN) |
| 13:30-14:00 |
L-17 |
Structural
Development of Thalidomide
Yuichi Hashimoto (The University of Tokyo, JAPAN) |
| 14:00-14:30 |
L-18 |
Conformational
Equilibria in the Wiskott-Aldrich Syndrome Protein Provide Avenues
for Inhibition of Function
Michael K. Rosen (University of Texas, Dallas TX, USA) |
| 14:30-15:00 |
L-19 |
Ligands
for Expression Cloning and Isolation of GABAB Receptors
Wolfgang Froestl (Novartis Pharma AG, Basel, SWITZERLAND) |
|
|
Chairman:
Masaji Ishiguro
|
| <Structural
Based Drug Designs-1> |
| 14:00-14:30 |
L-20 |
High Throughput
Crystallography and Drug Discovery
Tom L. Blundell (University of Cambridge, UK) |
| 14:30-15:00 |
L-21 |
Achieving
Extremely High Binding Affinity in Drug Design
Ernesto Freire (Johns Hopkins University, Baltimore MD, USA)
|
| 15:00-15:30 |
L-22 |
New Approaches
to Structure-based de Novo Design
Hans-Joachim Böhm (F. Hoffman-La Roche, Basel, SWITZERLAND)
|
| 15:30-16:00 |
|
<Coffee
Break> |
|
|
Chairman:
Tom Perun
|
| <Structural
Based Drug Designs-2> |
| 16:00-16:30 |
L-23 |
Discovery
and Development of the Orally Active Influenza Neuraminidase Inhibitor,
GS 4104 (Tamiflu®)
Choung U. Kim (Gilead Sciences, Inc., Foster City CA, USA) |
| 16:30-17:00 |
L-24 |
Crystal Structures
of the EGF Receptor Family
Colin W. Ward (CSIRO Health Sciences and Nutrition, Melbourne, AUSTRALIA)
|
| 17:00-17:30 |
L-25 |
Modulation
of Interleukin-6 Signaling Using the Structure of the Extracellular
Complex
Joseph N. Varghese (C.S.I.R.O. Division of Health Sciences & Nutrition,
Melbourne, Australia) |
|
|
Chairman:
Toru Fukuyama
|
| <Combinatorial
Biosynthesis> |
| 14:00-14:30 |
L-26 |
New Pharmaceuticals
from Genetic Engineering
Gary W. Ashley (Kosan Biosciences, Inc., Hayward CA, USA) |
| 14:30-15:00 |
L-27 |
Learning
Nature's Strategies for Making Unusual Sugars: Pathways, Mechanisms
and Biosynthetic Applications
Hung-Wen Liu (University of Texas, Austin TX, USA) |
| <Antimicrobial
Agents> |
| 15:00-15:30 |
L-28 |
Design,
Synthesis and Studies of New Antimicrobial Agents and Drug Delivery
Systems
Marvin J. Miller (University of Notre Dame, Notre Dam IN, USA) |
| 15:30-16:00 |
|
<Coffee
Break> |
|
|
Chairman:
Yoshiaki Kiso
|
| <Antibody
as Drugs> |
| 16:00-16:30 |
L-29 |
Advances
in Antibody Therapy: CNTO 95, A Fully Human Monoclonal Antibody to
Integrins αVβ3 and αVβ5
Has Direct Anti-Tumor and Antiangiogenic Activity
George A Heavner (Centocor, Inc., Malvern PA, USA) |
| 16:30-17:00 |
L-30 |
Targeting
HER2 Implications for Cancer Treatment
Mark Pegram (University of California, Los Angeles CA, USA) |
| <Mechanism-based
Drug Design> |
| 17:00-17:30 |
L-31 |
Mechanism-based
Drug Design
Thomas I. Kalman (The State University of New York, Buffalo NY, USA)
|
|